Governance at a Glance
|Board Members||Audit||Compensation||Corporate Governance and Nominating||Independent Investment||Succession|
Dr. Frost has been the CEO and Chairman of OPKO since March 2007. Previously, Dr. Frost served at Teva Pharmaceutical Industries, Limited ("Teva") as both Chairman of the Board and Vice Chairman. Dr. Frost served as Chairman of the Board of Directors and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He also served as chairman for Key Pharmaceuticals, Ladenburg Thalmann Financial Services and was a director of Continucare Corporation and Castle Brands, Inc. He was also a Governor and Co-Vice-Chairman of the American Stock Exchange.
Dr. Frost is a past chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of Regents of The Smithsonian Institution, and the Skolkovo Foundation Scientific Advisory Council in Russia.
Dr. Frost is a director of Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases.
Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer at OPKO since May 2007 and as a director since February 2007. Previously, Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical, and Neovasc, Inc.
Dr. Hsiao has served since 2008 as Chairman of the Board of Non-Invasive Monitoring Systems, Inc., a medical device company and was named Interim CEO of the company in 2012. Dr. Hsiao is also a director of TransEnterix, Inc., a medical device company, and Cocrystal Pharma, Inc.
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a director since February 2007. Previously, Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.
Mr. Rubin currently serves on the board of directors of Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, Inc., a medical device company; Cocrystal Pharma, Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses; ChromaDex Corp., a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, Inc. a company developing and marketing medical specialty vascular devices, and Red Violet, Inc., leading analytics and information solutions provider.
Mr. Rubin previously served as a director of Castle Brands, Inc., Dreams, Inc., Safestitch Medical, Inc., Cogent, Inc., PROLOR Biotech, Inc., BioCardia, Inc., and VBI Vaccines, Inc.
Jon R. Cohen
As Executive Chairman, Dr. Cohen has overall responsibility for Bioreference Laboratory and GeneDx. BioReference is one of the largest clinical laboratories in the United States. Dr. Cohen has more than 30 years of healthcare experience as a seasoned strategic leader with extensive P/L and operational responsibility and a successful track record of growing existing business and developing new business ventures. Previously, Dr. Cohen served for over nine years as a Senior Executive and named executive officer at Quest Diagnostics. Originally as Chief Medical Officer, most recently as Senior Vice President and Group Executive - Diagnostic Solutions. His business responsibilities during his tenure included the hospital reference business, cancer services, pathology services, sports diagnostics, and professional lab services, Quest's comprehensive offerings to hospitals and health systems.
Before joining Quest, Dr. Cohen served Senior Advisor to New York Governor David A. Paterson responsible for all strategy and planning after having run for Lieutenant Governor of New York in 2006 on a platform of healthcare reform. For seven years he served as Chief Medical Officer at North Shore-Long Island Jewish Health System (Northwell Health). In 2010, he was named one of the nation's top 50 most powerful physician executives by Modern Healthcare. His 2012 TEDMED, "Why Don't Patients Act Like Consumers?" was recently ranked the # 1 TEDMED talk that every healthcare executive needs to watch.
A vascular surgeon, he completed his residency in surgery at New York Presbyterian Hospital/Weill Cornell Medical Center and fellowship at the Brigham and Women's Hospital at Harvard Medical School.
Richard A. Lerner, M.D.
Dr. Lerner has served as a director of OPKO since March 2007. Previously, from 1986 until 2011, Dr. Lerner previously served as President of The Scripps Research Institute, a private, non-profit biomedical research organization, and is currently serving as an institute professor. Dr. Lerner is a member of numerous scientific associations, including the National Academy of Science and the Royal Swedish Academy of Sciences. He previously served as a director of Kraft Foods, Inc., Xencor, a privately-held biotechnology company, Teva Pharmaceuticals Industries, Ltd., Sequenom, Inc., a life sciences company, and on the Siemens' Advisory Board for Molecular Medicine of Siemens AG.
Dr. Lerner also currently serves as director of Intra-Cellular Therapies, a privately-held biotechnology company, and Zebra Biologics, Inc., a privately-held pre-clinical stage biopharmaceutical company.
John A. Paganelli
Mr. Paganelli has served as a director of OPKO since December 2003. Previously, Mr. Paganelli served as OPKO's Interim CEO and secretary, and Chairman of OPKO's Board of Directors until 2007. Mr. Paganelli also served as President and CEO of Transamerica Life Insurance Company of New York.
Since 1987, Mr. Paganelli has been a partner in RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, LLC, an investment company, and is Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization. Mr. Paganelli was also an officer and director-stockholder of Mike Barnard Chevrolet, Inc., an automobile dealership. Mr. Paganelli also serves as a director of Western New York Energy, LLC. Mr. Paganelli previously served on the Board of Trustees of Paul Smith's College and the Board of Managers of Bridge Financial Services, LLC.
Richard C. Pfenniger, Jr.
Mr. Pfenniger has served as a director of OPKO since January 2008. Mr. Pfenniger served as CEO and President for Continucare Corporation, a provider of primary care physician and practice management services, and as Chairman of the Board of Directors of Continucare Corporation until 2011. Mr. Pfenniger has also served as the CEO and Vice Chairman of Whitman Education Group, Inc.
Prior to joining Whitman, he served as the Chief Operating Officer of IVAX and as the Senior Vice President-Legal Affairs and General Counsel of IVAX. Mr. Pfenniger currently serves as a director of GP Strategies Corporation, a corporate education and training company, TransEnterix Inc., a medical device company pioneering the use of robotics, IntegraMed America, and BioCardia, Inc., a clinical-stage regenerative medicine company. He also serves as the Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science.
Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Yu has been a Director since 2009. Previously, she served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Since 2013, she has been a Distinguished Chair Professor at Chang Gung Memorial Hospital at Linkou, and Chang Gung University in Taiwan.
Dr. Yu has also served as a Professor of Pediatrics for both the National Taiwan University and the University of California in San Diego, where she was the Chief of Pediatric Hematology Oncology. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations.
Richard M. Krasno, Ph.D.
Dr. Krasno was appointed to the OPKO Board in 2017. Previously, Dr. Krasno served as executive director of the William R. Kenan, Jr. Charitable Trust and as President of the four affiliated William R. Kenan, Jr. Funds.
Prior to joining the Trust, Dr. Krasno was the President of the Monterey Institute of International Studies in Monterey, California. Dr. Krasno also served as a director of the University of North Carolina Health Care System and as chairman of the board of directors until 2012. He has also served as President and Chief Executive Officer of the Institute of International Education in New York, and as Deputy Assistant Secretary of Education in Washington, D.C.
Dr. Krasno currently serves as a director of Ladenburg Thalmann and BioCardia, Inc. and previously served as a director of Castle Brands, Inc. Dr. Krasno holds a Bachelor of Science from the University of Illinois and a Ph.D. from Stanford University.
Robert S. Fishel, M.D.
Dr. Fishel, an eminent cardiologist, serves as a director of several private companies. He is a director and founder of Florida Electrophysiology Associates and has been the CEO and President since 1997, a director and senior managing partner of Renaissance Properties since 1989, a director and founding partner of Catalyst Development Partners since 2009; a director and President of ALSAR Ltd Partnership since 1996, and a director and founder of NewPace Medical and its Chief Medical Officer since 2012. Dr. Fishel is an Affiliate Associate Professor of Medicine at the Charles E. Schmidt College of Medicine, Florida Atlantic University School of Medicine's Division of Integrated Sciences.
Roger J. Medel, M.D.
Dr. Medel is the co-founder of MEDNAX, Inc., a national health solutions partner comprised of the nation’s leading providers of physician services, and has served as a director of MEDNAX since 1979. Dr. Medel served as MEDNAX’s President until May 2000 and again from March 2003 until May 2004. He served as Chief Executive Officer of MEDNAX from 1979 until December 2002, and again from March 2003 until July 2020 when he retired. Dr. Medel has served as a member of the Board of Trustees of the Dana Farber Cancer Institute, Inc. since January 2016. He was a member of the Board of Trustees of the University of Miami from January 2004 to February 2012. Dr. Medel actively participates as a member of several medical and professional organizations and from June 2006 to April 2009, served on the Board of Directors of MBF Healthcare Acquisition Corp.